2018
Primary Hyperparathyroidism
Insogna KL. Primary Hyperparathyroidism. New England Journal Of Medicine 2018, 379: 1050-1059. PMID: 30207907, DOI: 10.1056/nejmcp1714213.Books
2014
Denosumab for Treatment of Hypercalcemia of Malignancy
Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for Treatment of Hypercalcemia of Malignancy. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3144-3152. PMID: 24915117, PMCID: PMC4154084, DOI: 10.1210/jc.2014-1001.Peer-Reviewed Original ResearchConceptsHypercalcemia of malignancyProportion of patientsDay 10Serum calciumBone resorptionCommon serious adverse eventsMedian response durationSerious adverse eventsSerum calcium levelsTreatment of hypercalcemiaDuration of responseNew treatment optionsBisphosphonate therapyPrimary endpointSecondary endpointsAdverse eventsBisphosphonate treatmentDurable responsesComplete responseAdvanced cancerTreatment optionsHematologic malignanciesResponse durationDenosumabCalcium levels
1980
Osteomalacia and Weakness From Excessive Antacid Ingestion
Insogna K, Bordley D, F. J, Lockwood D. Osteomalacia and Weakness From Excessive Antacid Ingestion. JAMA 1980, 244: 2544-2546. PMID: 7431592, DOI: 10.1001/jama.1980.03310220042025.Peer-Reviewed Original ResearchConceptsAluminum hydroxide-containing antacidElevated alkaline phosphatase levelsSerum calcium levelsAlkaline phosphatase levelsAntacid ingestionBone painPhosphate malabsorptionSevere hypophosphatemiaX-ray filmsInitial laboratory studiesPhysician awarenessUrinary phosphorusPatient's failureDietary phosphateCalcium levelsPhosphatase levelsOsteomalaciaFurther studiesHypercalciuriaHypophosphatemiaMalabsorptionPainAntacidsFailureSyndrome